ANI Pharmaceuticals ANIP Current maturities of long-term debt

Current maturities of long-term debt at other companies

Aurinia PharmaceuticalsAUPH

——

IncyteINCY

——

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Market cap$1.88B+18.3%

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: ANI Pharmaceuticals’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is ANI Pharmaceuticals's current maturities of long-term debt?: ANI Pharmaceuticals (ANIP) reported current maturities of long-term debt of $104K in Q4 2025.